Cellectis Acquires Exclusive License to TAL Effector Patents from University of Minnesota

Paris, January 20, 2011 – Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.  The exclusive license granted to Cellectis covers all uses of the technology in any field. Thetechnology has shown promising